Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Diabetes: CGM Goes Mainstream

Executive Summary

Getting a breakthrough medical device from the drawing board into mainstream use is the primary goal of every manufacturer, but a variety of factors influences how quickly a device reaches that goal - if at all. Right now, that process is playing out in the diabetes market, where continuous glucose monitoring (CGM) is moving closer to becoming a staple of effective diabetes treatment. The three companies that produce CGM devices - Medtronic, DexCom, and Abbott Laboratories - are very active in demonstrating the value of this technology, but other companies are stepping up in the market. Meanwhile, the focus on CGM is having an effect on other products, including insulin pumps.

Related Content


Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts